According to Smith & Nephew 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 2.50. At the end of 2024 the company had a P/S ratio of 1.88.
Year | P/S ratio | Change |
---|---|---|
2024 | 1.88 | -12.38% |
2023 | 2.15 | -4.36% |
2022 | 2.24 | -23.82% |
2021 | 2.95 | -25.54% |
2020 | 3.96 | -4.39% |
2019 | 4.14 | 23.07% |
2018 | 3.36 | 5.86% |
2017 | 3.18 | 12.93% |
2016 | 2.81 | -18.74% |
2015 | 3.46 | -3.29% |
2014 | 3.58 | 22.91% |
2013 | 2.91 | 21.39% |
2012 | 2.40 | 19.06% |
2011 | 2.02 | -14.64% |
2010 | 2.36 | -1.95% |
2009 | 2.41 | 60.42% |
2008 | 1.50 | -50.84% |
2007 | 3.05 | -14.06% |
2006 | 3.55 | 3.99% |
2005 | 3.42 | -56.01% |
2004 | 7.77 | 17% |
2003 | 6.64 | 4.11% |
2002 | 6.38 | -10.68% |
2001 | 7.14 |
Company | P/S ratio | P/S ratio differencediff. | Country |
---|---|---|---|
![]() Johnson & Johnson JNJ | 4.23 | 48.34% | ๐บ๐ธ USA |
![]() Stryker Corporation SYK | 6.21 | 117.72% | ๐บ๐ธ USA |
![]() Edwards Lifesciences EW | 7.96 | 179.02% | ๐บ๐ธ USA |
![]() Boston Scientific BSX | 8.41 | 194.71% | ๐บ๐ธ USA |
![]() Orthofix Medical
OFIX | 0.5357 | -81.22% | ๐บ๐ธ USA |
![]() CONMED CNMD | 1.26 | -55.86% | ๐บ๐ธ USA |